Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Enzolinion Apr 22, 2018 10:31am
135 Views
Post# 27923105

March 7 Post by KING "George"

March 7 Post by KING "George"Well some of these points have happened, now its a waiting game for the rest!!!! Great potential 

Spoke with Rob Farrell last night - here are the take aways:

1) Branch out will be not only cover GvHD with CBD - more clinical trials will be happening in paralel which will be leading to more news more often. Both companies are very reputable (one is Canadian) but no more can be said and we can't know until news is released. The branch out is because of the success of the GvHD trials and has nothing to do with "a backup" plan of some sort.

2) U.S. Patent that was Granted will be issued any day now. PR will be made the moment it is issued (could be any day).

3) There will be a couple more payments to Salzman via common shares.

4) Branch out news will be a good news letter to investors followed by some more good news there after.

5) GvHD clinical trials are going great and patients so far are seeing positive effects in Phase 2.

6) Share price will be effected for the better in the near future.

here people.

Spoke with Rob Farrell last night - here are the take aways:

1) Branch out will be not only cover GvHD with CBD - more clinical trials will be happening in paralel which will be leading to more news more often. Both companies are very reputable (one is Canadian) but no more can be said and we can't know until news is released. The branch out is because of the success of the GvHD trials and has nothing to do with "a backup" plan of some sort.

2) U.S. Patent that was Granted will be issued any day now. PR will be made the moment it is issued (could be any day).

3) There will be a couple more payments to Salzman via common shares.

4) Branch out news will be a good news letter to investors followed by some more good news there after.

5) GvHD clinical trials are going great and patients so far are seeing positive effects in Phase 2.

6) Share price will be effected for the better in the near future.


Bullboard Posts